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Novel mode of ligand binding by the SH2 domain of the human
XLP disease gene product SAP/SH2D1A
Shun-Cheng Li*, Gerald Gish*, Daiwen Yang†, Alison J. Coffey‡, 
Julie D. Forman-Kay§, Ingemar Ernberg¶, Lewis E. Kay† and Tony Pawson*
Background: The Src homology 2 (SH2) domains of cytoplasmic signaling
proteins generally bind phosphotyrosine (pTyr) sites in the context of carboxy-
terminal residues. SAP (also known as SH2D1A or DSHP), the product of the
gene that is mutated in human X-linked lymphoproliferative (XLP) disease,
comprises almost exclusively a single SH2 domain, which may modulate T-cell
signaling by engaging T-cell co-activators such as SLAM, thereby blocking
binding of other signaling proteins that contain SH2 domains. The SAP–SLAM
interaction can occur in a phosphorylation-independent manner. 
Results: To characterize the interaction between SAP and SLAM, we
synthesized peptides corresponding to the SAP-binding site at residue Y281 in
SLAM. Both phosphorylated and non-phosphorylated versions of an 11-residue
SLAM peptide bound SAP, with dissociation constants of 150 nM and 330 nM,
respectively. SLAM phosphopeptides that were truncated either at the amino or
carboxyl terminus bound with high affinity to SAP, suggesting that the SAP
SH2 domain recognizes both amino-terminal and carboxy-terminal sequences
relative to the pTyr residue. These results were confirmed by nuclear magnetic
resonance (NMR) studies on 15N- and 13C-labeled SAP complexed with three
SLAM peptides: an amino-terminally truncated phosphopeptide, a carboxy-
terminally truncated phosphopeptide and a non-phosphorylated Tyr-containing
full-length peptide.
Conclusions: The SAP SH2 domain has a unique specificity. Not only does it
bind peptides in a phosphorylation-independent manner, it also recognizes a
pTyr residue either preceded by amino-terminal residues or followed by
carboxy-terminal residues. We propose that the three ‘prongs’ of a peptide
ligand (the amino and carboxyl termini and the pTyr) can engage the SAP SH2
domain, accounting for its unusual properties. These data point to the flexibility
of modular protein-interaction domains.
Background
Signaling by protein tyrosine kinases involves binding of
Src homology 2 (SH2) domains to specific phosphotyro-
sine (pTyr)-containing motifs, such as those found on acti-
vated cell-surface receptors or associated subunits [1,2].
SH2 domains are usually located in larger polypeptides,
with additional interaction or catalytic modules that regu-
late intracellular signaling pathways. Typically, the associ-
ation of SH2 domains with Tyr-containing motifs depends
on phosphorylation of the ligand and, indeed, the majority
of the binding energy comes from the interaction of pTyr
with a conserved pocket on the SH2 domain [3,4]. Addi-
tional contacts are provided by SH2 residues that recog-
nize 3–6 amino acids immediately carboxy terminal to the
pTyr, in a fashion that varies from one SH2 domain to
another [4–7]. This ability to discriminate between differ-
ent pTyr motifs provides an important element of speci-
ficity in signaling by tyrosine kinases [8]. 
Although they lack intrinsic catalytic activity, cytokine
and immune receptors commonly signal through associ-
ated tyrosine kinases, which initiate a complex series of
SH2-mediated interactions required both for T-cell or
B-cell activation [9,10] and for attenuation of receptor
signaling [11]. Intriguingly, an SH2 domain protein (vari-
ously named SAP, SH2D1A and DSHP) expressed in T
cells has recently been shown to play a crucial and unique
role in the immune response to Epstein–Barr virus (EBV)
infection [12–14].
SAP is encoded by the gene mutated in X-linked lympho-
proliferative disease (XLP), or Duncan disease. Males
with XLP mutations are unable to control an EBV infec-
tion, which consequently induces an unregulated expan-
sion of polyclonal B and T cells, accompanied by either
severe infectious mononucleosis, acquired hypogamma-
globulinemia or malignant lymphoma, and invariably
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results in death [15,16]. The SAP protein consists almost
entirely of a single SH2 domain, flanked by 5 amino-ter-
minal and 26 carboxy-terminal amino acids. A number of
XLP mutations have been described, including deletions
and stop codons that truncate the SH2 domain [12–14], as
well as missense mutations that affect the Arg32, Thr53
and Val102 SH2 residues [13]. SAP is expressed in T
cells, rather than B cells, suggesting that its role lies in
regulating the ability of T cells to control EBV-infected B
cells [12–14]. As SAP lacks any obvious effector domain, it
may compete for the binding of other SH2 proteins to
pTyr-containing motifs, and thereby modulate the inten-
sity and duration of T-cell signaling. Consistent with this
possibility, SAP was also identified as a protein that binds
a Tyr-containing motif within the T-cell co-activator sig-
nalling lymphocyte-activation molecule (SLAM). In
keeping with the model that SAP may obstruct the access
of other SH2-containing proteins to pTyr motifs, SAP
inhibits binding of the Shp2 tyrosine phosphatase to phos-
phorylated SLAM [12]. Intriguingly, however, although
SAP binds to a specific site flanking Tyr281 in the SLAM
cytoplasmic region, phosphorylation appears not to be
essential for stable binding. These data suggest that the
SAP SH2 domain has an unusual binding specificity.
Here, we probed the mechanisms by which SAP may bind
to both phosphorylated and non-phosphorylated peptides.
Results
The SAP SH2 domain binds with high affinity to both Tyr-
and pTyr-containing SLAM peptides
To characterize the SAP–SLAM interaction in more
detail, we synthesized a non-phosphorylated peptide cor-
responding to residues 276–286 in SLAM. We termed this
peptide n–Y–c to denote the fact that it contains stretches
of both amino-terminal and carboxy-terminal residues
flanking the central Tyr281 site. For the purpose of com-
parison, we also synthesized a pTyr-containing phospho-
peptide, pY–c, that consists primarily of pTyr281 and
following carboxy-terminal residues (amino acids 279–286
of SLAM). The peptide pY–c resembles a conventional
SH2 domain ligand, as it contains the sequence
pTyr–Ala–Gln–Val typical of motifs recognized by group
II SH2 domains [6,17]. Each of these peptides was labeled
with fluorescein at its amino terminus through a linker of
3–4 hydrophilic residues (Table 1). We performed fluores-
cence polarization studies on the fluorescein-labeled pep-
tides, F–n–Y–c and F–pY–c, by adding varying
concentrations of purified, recombinant SAP protein. Both
peptides F–n–Y–c and F–pY–c bound strongly to SAP in a
concentration-dependent manner (Figure 1a), and reached
saturation at micromolar concentrations of SAP protein,
suggesting a single-site, bimolecular interaction in each
case. The dissociation constants of the peptide–SAP com-
plexes were 150 nM for the pTyr-containing peptide
F–pY–c and 330 nM for the Tyr-containing peptide
F–n–Y–c. These results clearly contrast with those from
other SH2 domains where at least a 1000-fold difference
in affinity is usually observed between the pTyr- and Tyr-
containing peptides [3].
The SH2 domain is responsible for SAP binding to these
peptides, as a glutathione-S-transferase (GST) fusion
protein containing residues 1–103, corresponding to the
SH2 domain, bound efficiently to both peptides F–n–Y–c
and F–pY–c (Figure 1b), whereas the GST protein alone
did not (data not shown). The dissociation constants of
these two interactions were estimated as 510 and 240 nM,
respectively (Table 1). Although these values are slightly
higher than those for wild-type SAP, the full-length
protein fused to GST also produced Kd values higher than
isolated SAP (Table 1). As discussed below, nuclear mag-
netic resonance (NMR) titration experiments indicated
that SAP residues carboxy-terminal to the SH2 domain
were not directly involved in peptide binding. Therefore,
phosphorylated and non-phosphorylated peptides specifi-
cally recognize the SAP SH2 domain.
The SAP SH2 domain recognizes both amino-terminal and
carboxy-terminal sequences relative to the pTyr residue
To explore the basis for the ability of SAP to bind both
phosphorylated and non-phosphorylated peptides, we
synthesized variants of the n–Y–c SLAM peptide with
substitutions or truncations, and measured their relative
affinities for the SAP SH2 domain by determining their
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Table 1
Affinities of fluorescein-labeled SLAM peptides for the SAP protein and its SH2 domain.
Peptide Sequence Dissociation constant (Kd, nM)
SAP GST–SAP GST–SH2
F–n–Y–c Fluorescein–GGR–KSLTIYAQVQK 330 ± 40 444 ± 50 510 ± 30
F–pY–c Fluorescein–   GGKK–TIpYAQVQK 150 ± 10 174 ± 22 240 ± 20
Peptide sequences corresponding to residues taken from sequences flanking the Tyr281 site (shown in bold) in SLAM are italicized. Residues
amino terminal to SLAM peptide sequences were added to increase peptide solubility in water and to serve as linker sequences for the attachment
of the fluorescein moiety [32]. Reported Kd values are averages over at least two independent experiments. 
ability to compete for SAP binding to the fluorescein-
labeled F–n–Y–c peptide. A peptide in which the Tyr
residue of peptide n–Y–c was replaced with pTyr
(n–pY–c) displayed a significantly higher affinity for the
SAP protein than the unphosphorylated n–Y–c peptide
(Table 2). This result suggests that, although tyrosine
phosphorylation is not essential for SAP binding to an
extended peptide motif, it nonetheless increases the affin-
ity of the target peptide. Nevertheless, the pTyr residue
in peptide n–pY–c does not play as significant a role as in
other SH2 domain ligands, where it is absolutely required
for stable binding. This idea is supported by results from
two other peptides, n–F–c and n–A–c, in which the
Tyr281 residue of peptide n–Y–c was replaced by Phe or
Ala, respectively. Peptide n–F–c exhibited only a moder-
ate decrease in binding affinity compared with peptide
n–Y–c, while peptide n–A–c retained over 10% of the
affinity observed for the parent peptide. These results
suggest that the SAP SH2 domain can bind peptide
sequences devoid of Tyr. 
The observation that peptide n–A–c still binds apprecia-
bly to SAP implies that the amino-terminal and carboxy-
terminal residues in peptide n–Y–c may interact with the
SAP SH2 domain. To probe their relative contributions to
SAP binding, we synthesized peptides with either amino-
terminal or the carboxy-terminal residues truncated rela-
tive to peptide n–Y–c. These peptides, n–Y and Y–c, were
essentially inactive in SAP binding, suggesting that
neither the amino-terminal nor the carboxy-terminal
sequence alone is sufficient for pTyr-independent SH2
binding. Strikingly, however, the phosphorylated versions
of these two peptides both bound strongly to SAP
(Table 2, Figure 2a). Indeed, peptide n–pY competed
twice as efficiently as peptide n–Y–c for SAP binding,
despite lacking carboxy-terminal residues that would nor-
mally be required for recognition by an SH2 domain. The
observation that peptide n–pY bound more tightly to SAP
than either peptide pY–c or peptide Ac–pY–c suggests
that the amino-terminal sequence of the peptide is critical
for high affinity SAP binding (Table 2). This may also
explain the decreased affinities of peptides pY–c and
Ac–pY–c compared with that of the fluorescein-labeled
peptide F–pY–c, which contains an extra amino-terminal
extension, GGKK, that could contribute to SAP binding.
As peptides pY–c and n–pY have only limited overlap
beyond the pTyr site, we tested whether they could
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Table 2
Relative affinities of the SLAM Y281 peptides.
Peptides Sequence Relative affinity (%)*
n–Y–c RKSLTI YAQVQK 100
n–pY–c KKSLTIpYAQVQK 465 ± 24
n–F–c RKSLTI FAQVQK 84 ± 9
n–A–c RKSLTI AAQVQK 13 ± 5
Y–c TI YAQVQK < 1
pY–c TIpYAQVQK 76 ± 10
Ac–pY–c Ac–IpYAQVQ 72 ± 14
n–Y RKSLTI YA < 1
n–pY RKSLTIpYA 225 ± 28
TIpYA TIpYA ND†
*Relative affinities of the peptides were calculated according to their
corresponding IC50 values (effective concentration for a 50% inhibition
of binding) derived from the competition experiments. Relative affinities
were normalized to that of peptide n–Y–c, set to 100%. Reported
numbers are based on two independent experiments. The (p)Y281
residue of SLAM and its substituted residues are highlighted in bold.
Another version of peptide n–Y–c was also synthesized which
contains a K instead of an R residue at the amino terminus. The two
peptides produced identical IC50 values within experiment errors (data
not shown). †Not determined; affinity was too low to be quantified.
Figure 1
Binding of (a) SAP and (b) the SH2 domain
of SAP fused to GST to peptides F–pY–c and
F–n–Y–c, as measured by fluorescein
polarization (in milli-polarization units, mP).
Independent experiments as shown were
used to calculate the dissociation constants
reported in Table 1.
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compete against each other for SAP binding (Figure 2b).
Peptide n–pY competed effectively for SAP binding to the
fluorescein-labeled peptide F–pY–c, suggesting that these
peptides engage overlapping sites on the SAP SH2
domain. Peptide n–Y–c could also displace peptide
F–pY–c for complex formation with SAP. Intriguingly,
peptide n–Y–c was slightly less effective than peptide
pY–c in inhibiting the interaction of peptide F–pY–c with
SAP (Figure 2b), in contrast to the result obtained when
peptide F–n–Y–c was used (Table 2). To probe the impor-
tance of the pTyr residue, we synthesized a short phos-
phopeptide, TIpYA, which proved incapable of competing
for SAP binding (Figure 2b; Table 2). Collectively, the
results from peptide competition studies suggest that two
of the three elements, namely an intact amino terminus,
an intact carboxyl terminus and a pTyr residue, must be
present in a SLAM peptide for tight binding to the SAP
SH2 domain.
NMR studies on SAP–SLAM peptide complexes
To gain further insight into the mechanism of peptide
recognition by the SAP SH2 domain, we labeled the SAP
protein with 13C and 15N, and performed NMR analysis
on SAP and its complexes with various SLAM peptides. A
heteronuclear single quantum correlation (HSQC) spec-
trum recorded on a free SAP sample, which correlates its
amide 15N resonance with those of its amide 1H, dis-
played features of a folded protein. Although most of the
amide resonances were well dispersed along the 1H
dimension, some sharp peaks were, however, found cen-
tered within a narrow region around 8.2 ppm in the 1H
dimension (Figure 3a), suggesting that residues corre-
sponding to these peaks are in an unfolded conformation.
To identify these residues, we titrated peptide n–Y–c into
a SAP sample that was labeled with both 13C and 15N,
with the aim of assigning the amide resonances of the
protein. Addition of the n–Y–c peptide into the protein
sample in a stepwise fashion induced drastic changes in
the HSQC spectra. Peaks corresponding to the free
protein gradually disappeared and, concomitantly, peaks
belonging to the peptide-complexed protein emerged
(data not shown). The resonances of the free and com-
plexed protein species are therefore in slow exchange (of
the order of seconds). Interestingly, while many amide
peaks exhibited large chemical-shift changes from the
free to peptide-complexed state, the sharp peaks identi-
fied in Figure 3a were essentially unperturbed by the
addition of peptide n–Y–c (Figure 3b). Upon backbone
assignment of the SAP protein complexed with peptide
n–Y–c, these peaks were identified as originating from
residues 105–127 in the SAP protein. These results
suggest that the carboxy-terminal tail of SAP beyond its
SH2 domain is unstructured and does not participate
directly in peptide interactions.
The secondary structural elements of the SAP protein
were subsequently predicted based on the deviations of
chemical shifts of the Hα, Cα, CO and Cβ nuclei for each
residue from those of a random coil [18]. The combina-
tion of the 1H and 13C chemical-shift indices allowed for
a consensus estimation of the secondary structures
[18,19] of the SAP protein, as shown in Figure 4. Specifi-
cally, two α-helical regions (residues 13–24 and 80–86)
and six β-strands (residues 28–32, 40–47, 50–54, 56–59,
61–66 and 75–77) were identified. The carboxy-terminal
residues of SAP were found in a random coil conforma-
tion as predicted from NMR titration studies. The
boundaries of the secondary structures identified through
these chemical-shift indices agree very well with those
predicted by sequence alignment [12] against the Abl
SH2 domain, whose structure is known [20]. As the SAP
SH2 domain shares 35% sequence identity with the Abl
SH2 domain, it is likely that they have similar structures.
Preliminary nuclear Overhauser effect (NOE) assign-
ments on the SAP–n–Y–c complex identified a number
of medium- and long-range NOEs that are consistent
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Figure 2
Free peptide competition for SAP binding to
fluorescein-labeled peptides (a) F–n–Y–c and
(b) F–pY–c. Data from a set of representative
experiments are shown. Repeated
experiments as shown were conducted to
generate the IC50 values used for the
calculation of relative affinities reported in
Table 2. The data shown are representative
but not inclusive.
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with a general fold for the SAP SH2 domain similar to
those of other SH2 domains (data not shown). 
To confirm the interactions between SAP and the pTyr-
containing peptides, we titrated peptides n–pY and pY–c
individually into isotope-enriched SAP samples. Both
peptides induced significant amide chemical-shift changes,
as did peptide n–Y–c (Figure 5). The titration patterns of
the two phosphopeptides were also similar to that of
peptide n–Y–c, implying that both the phosphorylated and
non-phosphorylated peptides bind tightly to the SAP
protein and have slow off-rates relative to the NMR time
scale once bound to SAP. It should be pointed out that
the amide peaks of SAP in the bound states are notably
different from one peptide complex to the other
(Figure 5), providing evidence of differences in the
details of the peptide–protein interactions among the
three SAP–peptide complexes. 
Discussion
Because the majority of the binding energy for phospho-
peptide recognition by a conventional SH2 domain
comes from engaging pTyr, dephosphorylation normally
abolishes stable SH2 binding [3]. Although pTyr binding
is a crucial determinant of SH2 domain–phosphopeptide
interactions, additional binding energy is usually
derived from interactions with residues carboxy-terminal
to the pTyr [4,6]. Amino-terminal sequences are gener-
ally not important, although a Val/Ile at the pY-2 posi-
tion plays a role in binding of the SH2 domains of the
Shp1 tyrosine phosphatase to the ITIM motifs of
inhibitory immune receptors [21]. 
Conventional SH2 domains are, however, not necessarily
fully optimized for phosphopeptide recognition. The
peptide-binding surfaces of SH2 domains can be rather
flat, and hydrogen bond interactions are sometimes medi-
ated by water molecules [22]. Dynamic measurements by
NMR spectroscopy have indicated that the side chains of
SH2 domain residues at the peptide–protein interface
can be highly mobile [23], and mutagenesis experiments
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Figure 3
HSQC (1H-15N) spectra of the 13C,15N-labeled SAP protein in
(a) free and (b) complexed states with peptide n–Y–c. Peaks
corresponding to the carboxy-terminal residues (105–128) of the
protein are labeled in (a), whereas a complete assignment of the
backbone amide resonances of the protein is shown in (b). Note that
the side chains of the Gln, Asn and Arg residues are not assigned.
Peaks corresponding to Val6, Gly49 and Tyr52 are folded along the
15N dimension and are denoted as italicized letters in (b). In addition,
amide resonances of Gly9 and Glu35 are shifted outside the
displaying window in the complexed state and are thus not 
shown in (b).
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Figure 4
Prediction of SAP secondary structure based on chemical-shift indices
[29,30] of 1H, 13CO, 13Cα and 13Cβ resonances of the SAP–n–Y–c
complex. Residues identified as belonging to a β-strand were assigned a
value of +1 and depicted as yellow stripes, while those belonging to an
α-helix were given a value of –1 and depicted as red stripes in the diagram.
Residues belonging to neither strand or helix were given a value of 0.
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have demonstrated that specificity results from a combina-
tion of inhibitory and attractive forces [24]. Furthermore,
it is possible to isolate mutant SH2 domains with
enhanced or altered phosphopeptide-binding affinity by
substitution of a single residue [8,25–27], suggesting that
the domain–peptide contacts are rather flexible. These
characteristics are physiologically important as they allow
conventional SH2 domains to bind relatively selectively to
specific motifs, yet impose a requirement for tyrosine
phosphorylation, which therefore serves as a switch to
induce complex formation. If the affinity for the unphos-
phorylated peptide were too high, the interaction would
no longer be phosphorylation dependent, and the off-rate
might be too low to permit rapid attenuation of signaling. 
The identification of the XLP disease product SAP, and
the observation that it can associate with the T-cell co-
activator SLAM in a phosphorylation-independent
manner, suggests that the recognition of non-phosphory-
lated sequences by an SH2 domain is biologically impor-
tant. We have characterized this interaction by binding
studies in vitro using a series of synthetic peptides
modeled on a SAP SH2-binding site in SLAM. We
started with an 11-mer peptide that included 5–6 residues
flanking each side of Tyr281. This peptide and its phos-
phorylated counterpart both bound tightly to the SH2
domain of SAP. Although the affinity of the phosphopep-
tide n–pY–c was 4–5-fold higher than that of the n–Y–c
peptide, the gain in affinity induced by tyrosine phospho-
rylation is much smaller than observed for other SH2
domains. In addition, the affinity of the unphosphory-
lated n–Y–c peptide for the SAP SH2 domain (Kd
~330 nM) is comparable to that of a typical SH2 domain
for its phosphorylated target [28].
In seeking to explain this atypical behaviour, we have
found that the SAP SH2 domain can recognize residues
amino terminal to the pTyr. This recognition appears to
be independent of carboxy-terminal residues, as a phos-
phopeptide containing primarily amino-terminal amino
acids and the pTyr (n–pY) bound with high affinity to
SAP, and indeed more strongly than a phosphopeptide
composed principally of carboxy-terminal residues (pY–c).
Our results therefore provide direct evidence that certain
SH2 domains, in addition to their ability to bind pTyr fol-
lowed by carboxy-terminal amino acids, can also stably
associate with pTyr preceded by amino-terminal residues.
Binding of amino-terminal or carboxy-terminal sequences
alone to SAP requires pTyr, although pTyr by itself does
not confer high-affinity binding. These studies clearly
divide the n–pY–c peptide into three distinct, yet interac-
tive regions: the amino-terminal and carboxy-terminal
regions, each of which may contain at least three residues,
and the pTyr site. By analogy with the ‘two-pronged plug
and socket’ model [5,29] portraying the interaction
between the Src SH2 domain and a high-affinity phospho-
peptide ligand, we propose a ‘three-pronged plug and
socket’ model to illustrate the interaction between the
SLAM peptide and the SAP SH2 domain (Figure 6).
Although this is highly simplified [30], it emphasizes the
tripartite nature of the SLAM–SAP interaction. Although
all three ‘prongs’ or sites must be engaged for maximal
affinity, the combination of any two prongs provides suffi-
cient binding energy for a stable complex between the
SAP SH2 domain and peptides with the appropriate
sequence (Figure 6). Cooperative binding between two or
three prongs is clearly evident from our binding data. 
These data are consistent with a scheme in which SAP
functions to block the activation of other SH2 domain pro-
teins in T cells, and thereby modulates T-cell function in a
fashion that is crucial for restraining EBV-infected B cells.
Our results suggest that SAP might operate in several dis-
tinct modes. Binding to an unphosphorylated site would
prevent its access to tyrosine kinases, and thereby block
phosphorylation and creation of a conventional SH2-binding
1360 Current Biology Vol 9 No 23
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Overlay of sections of HSQC spectra of the free SAP and SAP complexed with peptides (a) n–Y–c, (b) n–pY and (c) Ac–pY–c. Peaks
corresponding to the free protein are denoted as single-contour, open circles, while peaks belonging to the peptide-bound protein are depicted as
multiple-contour, filled circles.
site. Alternatively, SAP could bind very tightly to a phos-
phorylated motif with appropriate flanking sequences and
thereby inhibit recognition by other SH2 domains. In
addition, SAP could bind less strongly to phosphorylated
sites with optimal residues only to the amino or carboxyl
termini. The finding that mutations of residues such as
Arg32 (corresponding to ArgβB5 in conventional SH2
domains), which plays a key role in pTyr recognition, and
Thr53 and Val102, which are not obviously involved in
pTyr binding, cause disease indicates that SAP-mediated
interactions are fine-tuned in vivo. Possibly ablating
binding to any one of the three prongs impairs SAP SH2
function sufficiently to cause disease.
Our results are consistent with a growing view that the
specificity, and therefore the functions, of protein-interac-
tion domains are more diverse than previously appreci-
ated. For example, the pTyr-binding (PTB) domain was
originally identified as a module in the Shc and IRS-1
adaptors that binds pTyr in the context of NPXpY motifs.
The PTB domains of proteins such as X11 and Numb
have, however, subsequently been found to bind a varied
set of unphosphorylated peptide ligands, some of which
contain Phe in place of Tyr, and to recognize residues
both carboxy- and amino-terminal to the Tyr/Phe ([31,32];
our unpublished results). Variations on the theme of target
binding may allow the cell to use a limited set of related
modules to control a wide range of biological functions.
Our results are also consistent with the recently deter-
mined structure of the SAP SH2 domain by Poy et al. [33],
which was published during the proof stage of this paper.
Material and methods
Peptide synthesis and binding studies
Peptides were synthesized on an Applied Biosystem 431A peptide
synthesizer using standard 9-fluorenyl methoxycarbonyl (Fmoc) solid
phase chemistry and purified following published procedures [32]. The
identities of the peptides were confirmed by mass spectrometry and
the concentrations of peptide stock solutions were measured accord-
ing to their absorbance at 264 nm using extinction coefficients of
1,752 M–1cm–1 for the pTyr and 840 M–1cm–1 for the Tyr residue [34].
Fluorescence polarization experiments were conducted on a Beacon
Fluorescence Polarization System (PanVera Co.) equipped with a
100 µl sample chamber. The fluorescein-labeled peptides were dis-
solved in a phosphate buffer, pH 6.0, containing 0.1 mM EDTA and
1.0 mM DTT. For competition studies, various concentrations of unla-
beled peptides were mixed with 0.8–1.0 µM SAP protein in the phos-
phate buffer in the presence of labeled peptides and the mixture was
allowed to stand at room temperature for 5 min before measurement.
All measurements were carried out at 25°C.
Protein preparation
A construct for the expression of the SAP protein was generated
through PCR amplification of the coding cDNA sequence for
SAP/SH2D1A using the following primers: 5′-primer, 5′-TTTCA-
CATATGGACGCAGTGGCTGTG-3′; 3′-primer, 5′-TTTAGGATC-
CTCCATCATGGGGCTTTCAGGCAGAC-3′. The purified PCR
product was subcloned into the expression vector pET-3A. The SAP
and SAP-SH2 domain GST fusion constructs were generated by PCR
amplification of the full coding region or that for residues 1–102 and
subcloning into a pGEX-KT vector. Protein production was carried out
as before [32]. For purification of the isolated SAP protein, bacterial
lysates containing SAP was subjected to 30 min of high-speed
(15,000 rpm) centrifugation before passage through an SP-
Sepharose Fast Flow column (Pharmacia Biotech) equilibrated with
10 mM Tris, 25 mM NaCl, pH 7.0. The column was then eluted with a
NaCl gradient from 50 mM to 500 mM in the equilibration buffer. The
SAP-containing factions were collected and further purified on a G75
Sephadex FPCL column (Pharmacia Biotech). For NMR studies, the
SAP protein was expressed in minimal medium using 15N–NH4Cl and
13C–glucose as the sole nitrogen and carbon sources, and purified as
stated above.
NMR spectroscopy
NMR experiments were carried out at 30°C on Varian Inova 500 and
600 MHz spectrometers equipped with z-axis pulse-field gradients.
Data were processed using NMRPipe [35] and analyzed with the
NMRView [36] software packages. 1HN, 15N, 13Cα, 13Cβ and 13C-
carbonyl assignments were obtained from (HB)CBCA(CO)-NNH,
HNCACB and HNCO spectra recorded using enhanced sensitivity
pulsed-field gradient methodology [37,38].
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Figure 6
Illustration of the interactions between the
SAP SH2 domain and the SLAM peptides: a
‘three-pronged plug’ depiction of the SAP
SH2 domain–peptide interactions.
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